Description of Business and Significant Accounting Policies (Details) (USD $)
Share data in Millions, except Per Share data, unless otherwise specified |
1 Months Ended | 3 Months Ended | 134 Months Ended | 0 Months Ended | 1 Months Ended | 0 Months Ended | 1 Months Ended | 0 Months Ended | 1 Months Ended | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2012
|
Mar. 31, 2010
|
Mar. 31, 2012
|
Mar. 31, 2013
|
Dec. 31, 2012
|
Oct. 28, 2010
GSK
Original Collaboration Agreement
|
Oct. 31, 2010
GSK
Original Collaboration Agreement
|
Jul. 17, 2012
GSK
Expanded Collaboration Agreement
|
Jul. 31, 2012
GSK
Expanded Collaboration Agreement
|
Mar. 31, 2013
GSK
Expanded Collaboration Agreement
|
Jul. 26, 2012
GSK
SPA
|
Jul. 17, 2012
GSK
SPA
|
Jul. 31, 2012
GSK
SPA
|
Mar. 31, 2013
GSK
SPA
|
|
Corporate Information, Status of Operations and Management Plans | ||||||||||||||
Percentage of development costs funded by the entity | 40.00% | |||||||||||||
Percentage of development costs funded by the counterparty | 60.00% | |||||||||||||
Price per share of common stock issued as part of the license and collaboration agreement (in dollars per share) | $ 5.70 | $ 3.74 | $ 5.70 | $ 4.56 | $ 4.56 | $ 6.30 | $ 6.30 | |||||||
Total purchase price (in dollars) | $ 18,600,000 | $ 18,600,000 | ||||||||||||
Ownership position in the company (as a percent) | 19.80% | 19.80% | ||||||||||||
Accumulated deficit | (336,347,000) | (318,889,000) | ||||||||||||
Common stock issued (in shares) | 11.50 | 4.95 | 2.90 | |||||||||||
Warrants issued (in shares) | 1.9 | |||||||||||||
Proceeds from the issuance of common stock and warrants (in dollars) | $ 62,000,000 | $ 17,100,000 | $ 62,063,000 | $ 193,441,000 | $ 31,000,000 | $ 31,000,000 | $ 18,600,000 | |||||||
Stock issued from collaboration agreement (in shares) | 4.90 | 6.90 | 6.87 | 2.90 | 2.90 |